
Canalia30 mg
Aristopharma Ltd.
Erosive Esophagitis (EE) Dexlansoprazole is an established, FDA-approved indication for healing of all grades of erosive esophagitis for up to 8 weeks in adults and adolescents 12 years of age and…
Dexlansoprazole is an established, FDA-approved indication for healing of all grades of erosive esophagitis for up to 8 weeks in adults and adolescents 12 years of age and older. Dexlansoprazole is also indicated for maintenance of healed erosive esophagitis and relief of heartburn for up to 6 months in adults (up to 16 weeks in patients 12 to 17 years of age).
Dexlansoprazole is an established indication for treatment of heartburn associated with symptomatic non-erosive GERD for 4 weeks in adults and adolescents 12 years of age and older.
The dose and duration of Dexlansoprazole treatment depend on the specific condition being treated and must be determined by a qualified healthcare professional; the information below is general prescribing guidance and is not a substitute for individual medical advice.
Diarrhea, abdominal pain, nausea, upper respiratory tract infection, vomiting, and flatulence are the most commonly reported side effects of Dexlansoprazole. In adolescents (12-17 years), headache, abdominal pain, diarrhea, nasopharyngitis, and oropharyngeal pain have also been reported with Dexlansoprazole.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.